Name: Latest research reports of IDFC First Bank Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: IDFC First Bank Ltd.
Rating: 5
Author: BOB Capital Markets Ltd.

Summary	Date	Stock	Author	LTP	Target	Price at reco (Change since reco%)	Upside(%)	Type	Report	Discuss
	27 Jan 2025	IDFC First Bank	BOB Capital Markets Ltd. Target	71.72	75.00	56.73 (26.42%)	4.57	Buy	pdf post cache	Broker Report IDFC First Bank (BUY): Subdued performance, elevated provisioning BOB Capital Markets Ltd. Earnings lower on account of higher slippages, moderate loan book growth pdf Copy Link Share on Share on Share on Share on Alert
	27 Jan 2025	ICICI Bank	BOB Capital Markets Ltd. Reco Target	1457.70	1415.00	1227.95 (18.71%)	Target met	Buy	pdf post cache	Broker Report ICICI Bank (BUY): Continue to demonstrate stable performance BOB Capital Markets Ltd. PAT growth of 15% YoY aided by stable credit cost and PPOP growth of 15% YoY pdf Copy Link Share on Share on Share on Share on Alert
	27 Jan 2025	Laurus Labs	BOB Capital Markets Ltd. Target	631.45	488.00	534.65 (18.11%)	22.72	Sell	pdf post cache	Broker Report Laurus Labs (SELL): Margin guidance shifted from 20% to closer to 20% for FY25E BOB Capital Markets Ltd. Revenue/EBITDA/PAT exceeded our estimates by 10.5%/46.6%/227%. EBITDA margin surpassed our estimate by 500bps pdf Copy Link Share on Share on Share on Share on Alert
	27 Jan 2025	DCB Bank	BOB Capital Markets Ltd. Target	146.90	140.00	117.79 (24.71%)	Target met	Buy	pdf post cache	Broker Report DCB Bank (BUY): Solid performance BOB Capital Markets Ltd. Robust business growth with strong advances growth above our estimates pdf Copy Link Share on Share on Share on Share on Alert
	25 Jan 2025	MphasiS	BOB Capital Markets Ltd. Reco Target	2551.60	2651.00	3009.30 (-15.21%)	Target met	Sell	pdf post cache	Broker Report Mphasis (SELL): Not a steady performing Tier-2 player yet BOB Capital Markets Ltd. 3QFY25 has yet again proven the volatility in Mphasis's business compared to its Tier-2 peers like Persistent & Coforge pdf Copy Link Share on Share on Share on Share on Alert
	24 Jan 2025	Dr. Reddy's Labs	BOB Capital Markets Ltd.	1311.50	1427.00	1224.40 (7.11%)	8.81	Hold	pdf post cache	Broker Report Dr Reddys Labs (HOLD): NRT business to require huge marketing spend BOB Capital Markets Ltd. North America sales missed our estimates and reported US$ 395mn in 3QFY25 vs US$ 445mn in 2QFY25 impacted by gRevlimid pdf Copy Link Share on Share on Share on Share on Alert
	24 Jan 2025	Coforge	BOB Capital Markets Ltd. Reco Target	1767.00	7072.00	9234.60 (-80.87%)	Target met	Sell	pdf post cache	Broker Report Coforge (SELL): On the journey to becoming a Tier-1 BOB Capital Markets Ltd. 3QFY25 was blockbuster quarter 8.4% growth QoQ in CC terms (our estimate-2.8%. Belied seasonality) pdf Copy Link Share on Share on Share on Share on Alert
	24 Jan 2025	Zensar Technologies	BOB Capital Markets Ltd.	823.55	700.00	831.75 (-0.99%)	Target met	Sell	pdf post cache	Broker Report Zensar Technologies (SELL): Headed towards double digit growth in FY26 BOB Capital Markets Ltd. Delivered better-than-expected revenue and margin. After a mid-single digit FY25, revenue growth in double digits in FY26 likely pdf Copy Link Share on Share on Share on Share on Alert
	24 Jan 2025	UltraTech Cement	BOB Capital Markets Ltd. Target	11205.00	13137.00	11285.85 (-0.72%)	17.24	Buy	pdf post cache	Broker Report Ultratech Cement (BUY): Geared for growth momentum; maintain BUY BOB Capital Markets Ltd. Healthy 10% YoY volume growth aids flat topline despite 9% dent in realisations in a challenging Q3; capacity utilisation at ~76% pdf Copy Link Share on Share on Share on Share on Alert
	23 Jan 2025	Polycab	BOB Capital Markets Ltd. Reco Target	6008.50	8090.00	6250.90 (-3.88%)	34.64	Buy	pdf post cache	Broker Report Polycab India (BUY): Growth momentum continues; eyes on Project Spring BOB Capital Markets Ltd. Healthy revenue growth at 20% YoY; EBITDAM expands on better W&C margins and reduced FMEG losses pdf Copy Link Share on Share on Share on Share on Alert
more loading

BOB Capital Markets Ltd. Broker Research reports

Latest broker research reports from BOB Capital Markets Ltd. buy, sell, hold, neutral recommendations along with share price targets forecast and upside.

IDFC First Bank (BUY): Subdued performance, elevated provisioning

ICICI Bank (BUY): Continue to demonstrate stable performance

Laurus Labs (SELL): Margin guidance shifted from 20% to closer to 20% for FY25E

DCB Bank (BUY): Solid performance

Mphasis (SELL): Not a steady performing Tier-2 player yet

Dr Reddys Labs (HOLD): NRT business to require huge marketing spend

Coforge (SELL): On the journey to becoming a Tier-1

Zensar Technologies (SELL): Headed towards double digit growth in FY26

Ultratech Cement (BUY): Geared for growth momentum; maintain BUY

Polycab India (BUY): Growth momentum continues; eyes on Project Spring

Advisor Screeners